tiprankstipranks
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
US Market
BMRN
BioMarin Pharmaceutical
RESEARCH TOOLSreports
Want to see BMRN full AI Analyst Report?

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

2,424 Followers
See the Price Targets and Ratings of:

BMRN Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
13 Buy
5 Hold
0 Sell
Based on 18 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$89.31
▲(63.46% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $89.31 with a high forecast of $120.00 and a low forecast of $55.00. The average price target represents a 63.46% change from the last price of $54.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","121":"$121","69.25":"$69.3","86.5":"$86.5","103.75":"$103.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.3125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$89.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,69.25,86.5,103.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.06,59.13230769230769,64.20461538461538,69.27692307692308,74.34923076923077,79.42153846153846,84.49384615384616,89.56615384615385,94.63846153846154,99.71076923076923,104.78307692307692,109.85538461538462,114.92769230769231,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.06,56.77173076923077,59.48346153846154,62.19519230769231,64.90692307692308,67.61865384615385,70.33038461538462,73.04211538461539,75.75384615384615,78.46557692307692,81.17730769230769,83.88903846153846,86.60076923076923,{"y":89.3125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.06,54.13230769230769,54.20461538461539,54.276923076923076,54.34923076923077,54.42153846153846,54.49384615384616,54.566153846153846,54.63846153846154,54.71076923076923,54.783076923076926,54.855384615384615,54.92769230769231,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":62.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$120.00Average Price Target$89.31Lowest Price Target$55.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on BMRN
Salveen Richter
Goldman Sachs
Goldman Sachs
$69
Hold
26.28%
Upside
Initiated
05/11/26
BioMarin reinstated with a Neutral at Goldman SachsBioMarin reinstated with a Neutral at Goldman Sachs
Canaccord Genuity Analyst forecast on BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$104→$116
Buy
112.30%
Upside
Reiterated
05/07/26
BioMarin price target raised to $116 from $104 at CanaccordBioMarin price target raised to $116 from $104 at Canaccord
Guggenheim Analyst forecast on BMRN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$86
Buy
57.39%
Upside
Reiterated
05/06/26
Guggenheim Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Morgan Stanley Analyst forecast on BMRN
Sean Laaman
Morgan Stanley
Morgan Stanley
$120→$119
Buy
117.79%
Upside
Assigned
05/06/26
BioMarin Buy Rating Reiterated on Amicus Acquisition Synergies and Long-Term Upside; $120 Price Target Unchanged
Barclays Analyst forecast on BMRN
Eliana Merle
Barclays
Barclays
$105
Buy
92.17%
Upside
Reiterated
05/06/26
Barclays Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Piper Sandler Analyst forecast on BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
$84
Buy
53.73%
Upside
Reiterated
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ADC Therapeutics (NYSE: ADCT), Crispr Therapeutics AG (NASDAQ: CRSP) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Bank of America Securities Analyst forecast on BMRN
Jason Gerberry
Bank of America Securities
Bank of America Securities
$85
Buy
55.56%
Upside
Reiterated
05/05/26
BioMarin: Buy Rating Reiterated on Amicus Acquisition Upside and Pipeline Catalysts; $85 Price Target Unchanged
Evercore ISI Analyst forecast on BMRN
Cory Kasimov
Evercore ISI
Evercore ISI
$110→$120
Buy
119.62%
Upside
Reiterated
05/05/26
BioMarin price target raised to $120 from $110 at Evercore ISIBioMarin price target raised to $120 from $110 at Evercore ISI
Stifel Nicolaus Analyst forecast on BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$68
Hold
24.45%
Upside
Reiterated
05/05/26
Stifel Nicolaus Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TD Cowen Analyst forecast on BMRN
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
119.62%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN) and Sanofi (Other OTC: SNYNF)
H.C. Wainwright Analyst forecast on BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$55
Hold
0.66%
Upside
Reiterated
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (NASDAQ: ONCY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Tactile Systems Technology (NASDAQ: TCMD)
Bernstein Analyst forecast on BMRN
William Pickering
Bernstein
Bernstein
$94→$82
Buy
50.07%
Upside
Assigned
05/05/26
BioMarin price target lowered to $82 from $94 at BernsteinBioMarin price target lowered to $82 from $94 at Bernstein
Wedbush Analyst forecast on BMRN
Yun Zhong
Wedbush
Wedbush
$94
Buy
72.04%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Crispr Therapeutics AG (NASDAQ: CRSP)
RBC Capital Analyst forecast on BMRN
Luca Issi
RBC Capital
RBC Capital
$66
Hold
20.79%
Upside
Reiterated
05/04/26
RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
Wells Fargo Analyst forecast on BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
$75
Buy
37.26%
Upside
Reiterated
03/16/26
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weaknessWells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on BMRN
Salveen Richter
Goldman Sachs
Goldman Sachs
$69
Hold
26.28%
Upside
Initiated
05/11/26
BioMarin reinstated with a Neutral at Goldman SachsBioMarin reinstated with a Neutral at Goldman Sachs
Canaccord Genuity Analyst forecast on BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$104→$116
Buy
112.30%
Upside
Reiterated
05/07/26
BioMarin price target raised to $116 from $104 at CanaccordBioMarin price target raised to $116 from $104 at Canaccord
Guggenheim Analyst forecast on BMRN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$86
Buy
57.39%
Upside
Reiterated
05/06/26
Guggenheim Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Morgan Stanley Analyst forecast on BMRN
Sean Laaman
Morgan Stanley
Morgan Stanley
$120→$119
Buy
117.79%
Upside
Assigned
05/06/26
BioMarin Buy Rating Reiterated on Amicus Acquisition Synergies and Long-Term Upside; $120 Price Target Unchanged
Barclays Analyst forecast on BMRN
Eliana Merle
Barclays
Barclays
$105
Buy
92.17%
Upside
Reiterated
05/06/26
Barclays Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Piper Sandler Analyst forecast on BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
$84
Buy
53.73%
Upside
Reiterated
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ADC Therapeutics (NYSE: ADCT), Crispr Therapeutics AG (NASDAQ: CRSP) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Bank of America Securities Analyst forecast on BMRN
Jason Gerberry
Bank of America Securities
Bank of America Securities
$85
Buy
55.56%
Upside
Reiterated
05/05/26
BioMarin: Buy Rating Reiterated on Amicus Acquisition Upside and Pipeline Catalysts; $85 Price Target Unchanged
Evercore ISI Analyst forecast on BMRN
Cory Kasimov
Evercore ISI
Evercore ISI
$110→$120
Buy
119.62%
Upside
Reiterated
05/05/26
BioMarin price target raised to $120 from $110 at Evercore ISIBioMarin price target raised to $120 from $110 at Evercore ISI
Stifel Nicolaus Analyst forecast on BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$68
Hold
24.45%
Upside
Reiterated
05/05/26
Stifel Nicolaus Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TD Cowen Analyst forecast on BMRN
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
119.62%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN) and Sanofi (Other OTC: SNYNF)
H.C. Wainwright Analyst forecast on BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$55
Hold
0.66%
Upside
Reiterated
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (NASDAQ: ONCY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Tactile Systems Technology (NASDAQ: TCMD)
Bernstein Analyst forecast on BMRN
William Pickering
Bernstein
Bernstein
$94→$82
Buy
50.07%
Upside
Assigned
05/05/26
BioMarin price target lowered to $82 from $94 at BernsteinBioMarin price target lowered to $82 from $94 at Bernstein
Wedbush Analyst forecast on BMRN
Yun Zhong
Wedbush
Wedbush
$94
Buy
72.04%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Crispr Therapeutics AG (NASDAQ: CRSP)
RBC Capital Analyst forecast on BMRN
Luca Issi
RBC Capital
RBC Capital
$66
Hold
20.79%
Upside
Reiterated
05/04/26
RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
Wells Fargo Analyst forecast on BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
$75
Buy
37.26%
Upside
Reiterated
03/16/26
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weaknessWells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
xxx
Success Rate
15/36 ratings generated profit
42%
Average Return
-0.46%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.46% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
21/44 ratings generated profit
48%
Average Return
-3.82%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 47.73% of your transactions generating a profit, with an average return of -3.82% per trade.
2 Years
xxx
Success Rate
17/44 ratings generated profit
39%
Average Return
-3.75%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 38.64% of your transactions generating a profit, with an average return of -3.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
7
15
14
13
15
Buy
2
10
14
13
5
Hold
8
12
8
7
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
37
36
33
26
In the current month, BMRN has received 20 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 89.31.
Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $0.77 with a range of $0.24 to $1.28. The previous quarter’s EPS was $0.54. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BMRN is $0.77 with a range of $0.24 to $1.28. The previous quarter’s EPS was $0.54. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $927.61M with a range of $808.00M to $986.00M. The previous quarter’s sales results were $778.62M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.
Next quarter’s sales forecast for BMRN is $927.61M with a range of $808.00M to $986.00M. The previous quarter’s sales results were $778.62M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 89.31.
    What is BMRN’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 63.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BMRN a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s price target?
            The average price target for BioMarin Pharmaceutical is 89.31. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $120.00 ,the lowest forecast is $55.00. The average price target represents 63.46% Increase from the current price of $54.64.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of BMRN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.